Table 4.
Long-term outcomes and recurrences.
| Author/Year | 3-Year OS, % | 5-Year OS, % | OS, Median Months (Range) | 3-Year DFS, % | 5-Year DFS, % | DFS, Median Months (Range) | Follow-Up, Median Months (Range) | Recurrence, n (%) | Sites, n (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liver | Lung | Peritoneum | Distant LN | PALN | Bone | Brain | Local | Ovary | Mediastinum | Other | |||||||||
| Min et al./2008 | / | / | 34 | / | / | 22 | 30 | 6 (100) | 6 (100) | 3 (50.0) | 0 | 0 | 0 | 2 (33.3) | 0 | 0 | 0 | 0 | 0 |
| Choi et al./2010 | 59.4 | 53.4; 56.6 (CSS) | 64 (17–111) | 49 | 22 | 14 | 29 (7–75) | 16 (66.7) | 4 (16.7) | 3 (12.5) | 3 (12.5) | 5 (20.8) | 7 (29.2) | 3 (12.5) | 1 (4.2) | 0 | 0 | 0 | 0 |
| Gagnière et al./2015 | 68 | 56 | / | 61 | 51 | / | 85 (4–142) | / | / | / | / | / | / | / | / | / | / | / | / |
| Song et al./2016 | 65.7 | / | 30.2 (9.1–94.2) | 40.2 | / | 20.3 (2.5–94.2) | 31 (9.1–103.1) | 9 (56.3) | 3 (18.8) | 2 (12.5) | 2 (12.5) | 2 (12.5) | 4 (25.0) | 1 (6.2) | 0 | 2 (12.5) | 0 | 0 | 0 |
| Ogura et al./2017 | / | 70.3 (CSS) | / | / | 60.5 | / | 58.8 (2.4–103.2) | 7 (43.8) | 2 (12.5) | 0 | 1 (6.2) | 2 (12.5) | 4 (25.0) | 0 | 0 | 0 | 0 | 0 | 0 |
| Bae et al./2018 | / | 33.9 | 37 (6–169) | / | 26.5 | / | / | 33 (67.3) | 8 (16.3) | 10 (20.4) | 2 (4.1) | 0 | 8 (16.3) | 1 (2.0) | 0 | 4 (8.2) | 0 | 0 | 2 (4.1) |
| Yamamoto et al./2019 | / | / | 25 (2–44) | / | / | 17 (2–44) | / | 3 (60) | 1 (20.0) | 1 (20.0) | 0 | 1 (20.0) | 1 (20.0) | 0 | 0 | 0 | 0 | 0 | 2 (40.0) |
| Kim et al./2020 | / | 87.5 | 84 (32–182) | / | 0 | 24 (6–46) | 50 (30–72) | 8 (50) | 0 | 2 (12.5) | 0 | 5 (31.2) | 0 | 0 | 0 | 1 (6.2) | 0 | 0 | 0 |
| Sakamoto et al./2020 | 63.2 | / | / | 26.3 | / | / | 30 (1.5–20.7) | / | / | / | / | / | / | / | / | / | / | / | / |
OS = Overall survival; DFS = Disease-free survival; LN = Lymph node; PALN = Para-aortic lymph node; CSS = Cancer-specific survival.